Kuros Biosciences Achieves Remarkable Sales Growth in 2025
Financial & Operational Highlights
- Direct sales of the MagnetOs™ product grew by 79% with revenue reaching USD 28.4 million in Q1 2025 (up from USD 15.8 million in the same quarter of the previous year).
- Total Medical Device sales surged by 82% to USD 28.8 million, marking the first time monthly revenues exceeded USD 10 million.
- The Group reported an EBITDA of USD 2.0 million, showing significant improvement compared to USD 1.2 million in Q1 2024.
- Adjusted EBITDA stood at USD 3.3 million, reflecting a margin of 11.6%.
- Operational cash flow remains positive, effectively supporting the upcoming expansion of production capacity.
- Cash and cash equivalents totaled USD 19.5 million, a stable figure compared to the prior quarter (USD 19.8 million).
- Kuros has made proactive investments to increase inventory in anticipation of tariffs, adding USD 2.8 million to stock levels and planning to diversify production operations in the U.S.
Regulatory, Commercial & Clinical Highlights
- MagnetOs Granules have gained commercial clearance in Brazil, and progress is being made for MagnetOs Putty, with both products also cleared for Lebanon.
- Promising clinical data has emerged, showcasing a 95.7% fusion rate in high-risk patients using MagnetOs in interbody fusion surgeries, reinforcing its efficacy.
In the initial three months of 2025, Kuros Biosciences, known for its cutting-edge bone healing technologies, shared a strong financial performance. Revenue from Direct MagnetOs product sales soared by 79%, climbing to USD 28.4 million in comparison to USD 15.8 million in the same period last year. The overall group revenue hit USD 28.8 million, reflecting an 82% increase, with unprecedented monthly revenue exceeding USD 10 million.
Kuros achieved an EBITDA of USD 2.0 million, demonstrating substantial growth from USD 1.2 million in Q1 of the prior year. The adjusted EBITDA, excluding one-time compensation costs, reached USD 3.3 million, thereby achieving an adjusted margin of 11.6%. Despite substantial investments in inventory (approximately USD 2.8 million) to prepare for potential tariffs, cash and equivalents remain securely at USD 19.5 million.
The company is currently assessing the recent U.S. tariff measures and their implications on medical devices and raw materials. While final impacts are yet to be determined, Kuros is actively taking steps to secure a reliable supply chain, including diversifying production and augmenting inventory levels.
Furthermore, Kuros is committed to broadening its global reach, having secured commercial clearances for its MagnetOs Granules in Brazil and Lebanon. These achievements mark crucial advances in making their innovative bone graft technology more accessible in key markets across Latin America and the Middle East.
Recent independent studies have further substantiated the clinical success of MagnetOs in challenging patient populations. According to a study involving 55 patients with various health challenges undergoing lumbar interbody fusion, MagnetOs demonstrated a remarkable fusion rate of 95.7% at the one-year mark.
- Sandhu et al. (Published: World Neurosurgery, 2025): This study reinforces the potential of MagnetOs in intricate cases, yielding a high fusion success rate (95.7%) in patients with multiple comorbidities.
- Davis et al. (Accepted: Orthopedic Reviews, 2025): This investigation evaluated MagnetOs Easypack Putty in 20 patients, showing a fusion success rate of 94.4%, even in a demographic with a high prevalence of obesity and diabetes.
The insights from these studies bolster Kuros’ ongoing Project Fusion, providing surgeons with the confidence to make decisions backed by solid evidence.
Chris Fair, CEO of Kuros Biosciences, remarked on the impressive quarter: "We experienced a robust start to 2025, achieving significant revenue totals. Our expansion into the extremity market, alongside our thriving spine collaboration with Medtronic, lays a solid foundation for future growth. This global performance is a testament to our proactive approach to current market dynamics. With new commercial clearances and strong sales momentum, we are poised for an exceptional year ahead. We are dedicated to empowering clinicians with innovations that facilitate evidence-based practices."
For further information, please contact:
Alexandre Müller
Investor Relations
Tel +41 43 268 32 31
Email: IR@kurosbio.com
Daniel Geiger
Chief Financial Officer
Tel +41 44 733 47 41
Email: daniel.geiger@kurosbio.com
About MagnetOs™
MagnetOs is distinguished by its unique NeedleGrip technology, which enhances bone growth even within softer tissues, promoting recovery and supporting the formation of new bone. This innovative approach aligns with the principles of osteoimmunology, resulting in more predictable surgical outcomes.
About Kuros Biosciences
Kuros Biosciences is committed to discovering and delivering groundbreaking biologic technologies across the globe. With facilities in the U.S., Switzerland, and the Netherlands, and listing on the SIX Swiss Exchange, their flagship product, MagnetOs, is revolutionizing bone grafting practices worldwide.
Frequently Asked Questions
What financial milestones did Kuros Biosciences achieve in 2025?
Kuros reported an 82% increase in total sales, reaching USD 28.8 million in Q1 2025, alongside a robust EBITDA growth.
What products contributed significantly to their revenue growth?
The Direct MagnetOs sales led the charge, reflecting a substantial increase of 79%, amounting to USD 28.4 million in Q1 2025.
How has Kuros Biosciences expanded its international presence?
Kuros secured commercial clearance for its products in Brazil and Lebanon, paving the way for wider access to its innovative technologies in Latin America and the Middle East.
What clinical evidence supports the effectiveness of MagnetOs?
Recent studies show significant fusion rates of 95.7% and 94.4% in high-risk patients, validating the clinical efficacy of MagnetOs.
What is the strategic response of Kuros to current tariff measures?
Kuros is increasing inventory levels and diversifying production locations to maintain a stable supply chain while evaluating the full implications of the new tariffs.
